Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as novel and potent TBK1 inhibitors : design, synthesis, biological evaluation, and molecular docking study
sABSTRACTTANK-binding kinase 1 (TBK1), a noncanonical member of the inhibitor-kappaB kinases (IKKs) family, plays a vital role in coordinating the signalling pathways of innate immunity, involving in the process of neuroinflammation, autophagy, and oncogenesis. In current study, based on rational drug design strategy, we discovered a series of 1H-pyrazolo[3,4-b]pyridine derivatives as potent TBK1 inhibitors and dissected the structure-activity relationships (SARs). Through the several rounds of optimisation, compound 15y stood out as a potent inhibitor on TBK1 with an IC50 value of 0.2 nM and also displayed good selectivity. The mRNA detection of TBK1 downstream genes showed that compound 15y effectively inhibited TBK1 downstream IFN signalling in stimulated THP-1 and RAW264.7 cells. Meanwhile, compound 15y exhibited a micromolar antiproliferation effect on A172, U87MG, A375, A2058, and Panc0504 cell lines. Together, current results provided a promising TBK1 inhibitor 15y as lead compound for immune- and cancer-related drug discovery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of enzyme inhibition and medicinal chemistry - 37(2022), 1 vom: 15. Dez., Seite 1411-1425 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Yin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1H-pyrazolo[3,4-b]pyridine |
|---|
| Anmerkungen: |
Date Completed 23.05.2022 Date Revised 28.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/14756366.2022.2076674 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34110440X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34110440X | ||
| 003 | DE-627 | ||
| 005 | 20231226011014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14756366.2022.2076674 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM34110440X | ||
| 035 | |a (NLM)35587686 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Yin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as novel and potent TBK1 inhibitors |b design, synthesis, biological evaluation, and molecular docking study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.05.2022 | ||
| 500 | |a Date Revised 28.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a sABSTRACTTANK-binding kinase 1 (TBK1), a noncanonical member of the inhibitor-kappaB kinases (IKKs) family, plays a vital role in coordinating the signalling pathways of innate immunity, involving in the process of neuroinflammation, autophagy, and oncogenesis. In current study, based on rational drug design strategy, we discovered a series of 1H-pyrazolo[3,4-b]pyridine derivatives as potent TBK1 inhibitors and dissected the structure-activity relationships (SARs). Through the several rounds of optimisation, compound 15y stood out as a potent inhibitor on TBK1 with an IC50 value of 0.2 nM and also displayed good selectivity. The mRNA detection of TBK1 downstream genes showed that compound 15y effectively inhibited TBK1 downstream IFN signalling in stimulated THP-1 and RAW264.7 cells. Meanwhile, compound 15y exhibited a micromolar antiproliferation effect on A172, U87MG, A375, A2058, and Panc0504 cell lines. Together, current results provided a promising TBK1 inhibitor 15y as lead compound for immune- and cancer-related drug discovery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 1H-pyrazolo[3,4-b]pyridine | |
| 650 | 4 | |a TBK1 inhibitors | |
| 650 | 4 | |a cancer therapy | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a structure–activity relationships (SARs) | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 700 | 1 | |a Tang, Haotian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Tiantian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Dongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tongchao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of enzyme inhibition and medicinal chemistry |d 2002 |g 37(2022), 1 vom: 15. Dez., Seite 1411-1425 |w (DE-627)NLM121560376 |x 1475-6374 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2022 |g number:1 |g day:15 |g month:12 |g pages:1411-1425 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14756366.2022.2076674 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2022 |e 1 |b 15 |c 12 |h 1411-1425 | ||